Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp-tebn with Liver-Directed Therapies in Metastatic Uveal Melanoma
NCT06626516Phase 2Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tebentafusp in Uveal melanoma (UM) (4 arms), sponsored by Thomas Jefferson University. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 30 days, 6-Month Liver-Specific Progression-Free Survival Rate and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06626516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626516.